Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer

Por Bottini, A, Berruti, A, Brizzi, M P, Bersiga, A, Generali, D, Allevi, G, Aguggini, S, Bolsi, G, Bonardi, S, Bertoli, G, Alquati, P, Dogliotti, L
Publicado em 2003

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

Por Bottini, A, Berruti, A, Bersiga, A, Brizzi, M P, Bruzzi, P, Aguggini, S, Brunelli, A, Bolsi, G, Allevi, G, Generali, D, Betri, E, Bertoli, G, Alquati, P, Dogliotti, L
Publicado em 2001

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

Por Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A
Publicado em 2008

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics

Por Oakes, SR, Vaillant, F, Lim, E, Lee, L, Breslin, K, Feleppa, F, Deb, S, Ritchie, ME, Takano, E, Ward, T, Fox, SB, Generali, D, Smyth, GK, Strasser, A, Huang, DCS, Visvader, JE, Lindeman, GJ
Publicado em 2012

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

Por Generali, D, Buffa, F M, Deb, S, Cummings, M, Reid, L E, Taylor, M, Andreis, D, Allevi, G, Ferrero, G, Byrne, D, Martinotti, M, Bottini, A, Harris, A L, Lakhani, S R, Fox, S B
Publicado em 2014

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Por Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL
Publicado em 2019-04-01

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

Por Koukourakis, M I, Giatromanolaki, A, Bottini, A, Cappelletti, M R, Zanotti, L, Allevi, G, Strina, C, Ardine, M, Milani, M, Brugnoli, G, Martinotti, M, Ferrero, G, Bertoni, R, Ferrozzi, F, Harris, A L, Generali, D
Publicado em 2014

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Por Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Publicado em 2013

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

Por Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Generali, D, Milani, M, Katsaros, D, Rigault de la Longrais, I A, Bellino, R, Donadio, M, Ardine, M, Bertetto, O, Danese, S, Sarobba, M G, Farris, A, Lorusso, V, Dogliotti, L
Publicado em 2005

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

Por Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Publicado no Br J Cancer (2015)